✦ LIBER ✦

TCT-173 Safety and Clinical Performance of the Drug Eluting Osiro Stent in the Treatment of Subjects With Single De Novo Coronary Artery Lesions-II (BIOFLOW-II)

✍ Scribed by Windecker, Stephan; Witzenbichler, Bernhard; Stangl, Karl; Slagboom, Ton; Neumann, Franz-Josef; Lefevre, Thierry; Ruiz-Salmeron, Rafael; Sabate, Manel; Piot, Cristophe; Richardt, Gert; Merkely, Béla; J, Goicolea; Bilger, Johannes; Schneider, Henrik; Barragan, Paul; Cook, Stéphane; Erne, Paul; Waksman, Ron; Haude, Michael

Book ID: 122106109
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 71 KB
Volume: 62
Category: Article
ISSN: 1558-3597
DOI: 10.1016/j.jacc.2013.08.907

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

TCT-69 Safety and clinical performance o

TCT-69 Safety and clinical performance of the drug eluting Osiro stent in patients with single de novo coronary artery lesions - II (BIOFLOW-II) -A quantitative analysis by IVUS and OCT-

✍ Lefevre, Thierry; Windecker, Stephan; Haude, Michael; Stangl, Karl; Sabate, Mane 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 70 KB

5-Year Clinical Outcomes of the ARTS II

5-Year Clinical Outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the Sirolimus-Eluting Stent in the Treatment of Patients With Multivessel De Novo Coronary Artery Lesions

✍ Patrick W. Serruys; Yoshinobu Onuma; Scot Garg; Pascal Vranckx; Bernard De Bruyn 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 878 KB

SPIRIT II STUDY: EVALUATION OF THE XIENC

SPIRIT II STUDY: EVALUATION OF THE XIENCE V EVEROLIMUS ELUTING CORONARY STENT IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS

✍ Onuma, Yoshinobu; Serruys, Patrick W.; the SPIRIT II Investigators, ; Center, Th 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Four-year clinical follow-up of the XIEN

Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial

✍ Scot Garg; Patrick W. Serruys; Karine Miquel-Hebert; on behalf of the SPIRIT II 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB 👁 2 views

## Abstract This report describes the 4‐year clinical outcomes of the SPIRIT II study, which randomized 300 patients to treatment with the XIENCE V everolimus‐eluting stent (EES), or the TAXUS paclitaxel‐eluting stent. At 4‐year clinical follow‐up, which was available in 256 (85.3%) patients, treat

Comparison of Everolimus-Eluting and Pac

Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention: The SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials

✍ Dean J. Kereiakes; Krishnankutty Sudhir; James B. Hermiller; Paul C. Gordon; Joa 📂 Article 📅 2010 🏛 American College of Cardiology 🌐 English ⚖ 939 KB

TCT-244: A Clinical Evaluation of the Pr

TCT-244: A Clinical Evaluation of the ProNOVA XR Polymer Free Sirolimus Eluting Coronary Stent System in the Treatment of Patients with De Novo Coronary Artery Lesions (EURONOVA Study)

📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 83 KB